Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acacia baileyana pollen is an allergenic extract derived from the pollen of the Cootamundra wattle (*Acacia baileyana*), a tree in the Fabaceae family. It is primarily used as a diagnostic tool for skin testing to identify IgE-mediated hypersensitivity and as a therapeutic agent for allergen immunotherapy (desensitization) in sensitized individuals. The extract works by interacting with specific IgE antibodies on mast cells and basophils during diagnostic testing and by modulating T-cell and B-cell responses during immunotherapy to induce clinical tolerance. First approved in the United States in 1972, it is produced by several specialized manufacturers of allergenic products, including Antigen Laboratories, Hollister-Stier Labs, and ALK-Abello.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Acacia baileyana pollen.